Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Pipeline Review, H2 2018
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Histone Deacetylase 8 - Pipeline Review, H2 2018'; Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules.
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Histone deacetylase 8 is an enzyme encoded by the HDAC8 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.
The report 'Histone Deacetylase 8 - Pipeline Review, H2 2018' outlays comprehensive information on the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, IND/CTA Filed and Preclinical stages are 1, 1 and 4 respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Colon Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Adenoid Cystic Carcinoma (ACC), Alzheimer's Disease, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Bone Disorders, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Mycosis Fungoides, Natural Killer Cell Lymphomas, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Renal Cell Carcinoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Histone Deacetylase 8 - Pipeline Review, H2 2018'; Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) pipeline Target constitutes close to 6 molecules.
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Histone deacetylase 8 is an enzyme encoded by the HDAC8 gene. It is responsible for the deacetylation of lysine residues on the N-terminal part of the core histones. It plays an important role in transcriptional regulation, cell cycle progression and developmental events.
The report 'Histone Deacetylase 8 - Pipeline Review, H2 2018' outlays comprehensive information on the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, IND/CTA Filed and Preclinical stages are 1, 1 and 4 respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Colon Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Adenoid Cystic Carcinoma (ACC), Alzheimer's Disease, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, B-Cell Non-Hodgkin Lymphoma, Bladder Cancer, Bone Disorders, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Human Immunodeficiency Virus (HIV) Infections (AIDS), Liver Cancer, Liver Fibrosis, Lung Cancer, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Mycosis Fungoides, Natural Killer Cell Lymphomas, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Renal Cell Carcinoma.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Overview
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
AlfaSigma SpA
Chipscreen Biosciences Ltd
HitGen LTD
NatureWise Biotech & Medicals Corp
Zhejiang Hisun Pharmaceutical Co Ltd
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Drug Profiles
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
largazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBM-BMX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-3595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tucidinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Jun 04, 2018: HUYA Bioscience International expanded oncology pipeline includes combination with checkpoint inhibitor for solid tumors
May 29, 2018: Chipscreen Biosciences Announces that a Pivotal Phase III Clinical Trial of Chidamide in Combination with Exemestane in Patients with Breast Cancer Reached Primary Endpoint
Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer
Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team
Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
Sep 03, 2015: HUYA Bioscience International Announces Epigenetic Breast Cancer Program
Aug 27, 2015: HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting
Mar 19, 2015: HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan
Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China
Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation
Nov 06, 2013: The CSO of Chipscreen Biosciences was invited to speak at “The 4th CPA-RSC Symposium on Medicinal Chemistry: Epigenetics as Targets for Drug Discovery”
Apr 16, 2013: Chipscreen Biosciences Announces Achievement Of Primary Endpoint In Chidamide Registrational Phase II Trial In China
Jul 24, 2012: Chidamide is scheduling to file NDA by the end of this year
Aug 23, 2010: Chidamide (CS055) obtained permission from SFDA to enter into Phase II and III clinic studies for NSCLC, Breast and Prostate cancer in China
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Overview
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
AlfaSigma SpA
Chipscreen Biosciences Ltd
HitGen LTD
NatureWise Biotech & Medicals Corp
Zhejiang Hisun Pharmaceutical Co Ltd
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Drug Profiles
HG-3001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
largazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBM-BMX - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-3595 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tucidinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Jun 04, 2018: HUYA Bioscience International expanded oncology pipeline includes combination with checkpoint inhibitor for solid tumors
May 29, 2018: Chipscreen Biosciences Announces that a Pivotal Phase III Clinical Trial of Chidamide in Combination with Exemestane in Patients with Breast Cancer Reached Primary Endpoint
Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer
Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team
Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
Sep 03, 2015: HUYA Bioscience International Announces Epigenetic Breast Cancer Program
Aug 27, 2015: HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting
Mar 19, 2015: HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan
Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China
Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation
Nov 06, 2013: The CSO of Chipscreen Biosciences was invited to speak at “The 4th CPA-RSC Symposium on Medicinal Chemistry: Epigenetics as Targets for Drug Discovery”
Apr 16, 2013: Chipscreen Biosciences Announces Achievement Of Primary Endpoint In Chidamide Registrational Phase II Trial In China
Jul 24, 2012: Chidamide is scheduling to file NDA by the end of this year
Aug 23, 2010: Chidamide (CS055) obtained permission from SFDA to enter into Phase II and III clinic studies for NSCLC, Breast and Prostate cancer in China
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AlfaSigma SpA, H2 2018
Pipeline by Chipscreen Biosciences Ltd, H2 2018
Pipeline by HitGen LTD, H2 2018
Pipeline by NatureWise Biotech & Medicals Corp, H2 2018
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2018
Dormant Projects, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AlfaSigma SpA, H2 2018
Pipeline by Chipscreen Biosciences Ltd, H2 2018
Pipeline by HitGen LTD, H2 2018
Pipeline by NatureWise Biotech & Medicals Corp, H2 2018
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2018
Dormant Projects, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AlfaSigma SpA
Chipscreen Biosciences Ltd
HitGen LTD
NatureWise Biotech & Medicals Corp
Zhejiang Hisun Pharmaceutical Co Ltd
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AlfaSigma SpA
Chipscreen Biosciences Ltd
HitGen LTD
NatureWise Biotech & Medicals Corp
Zhejiang Hisun Pharmaceutical Co Ltd
